comprehensive -WSS

comprehensive

author：focus 2025-10-02 20:06:10 - browse：94

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Medicare isn't yet testing food as medicine

focus

WSS

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

How to make the FDA’s new prescription one

Study fuels hope CAR

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Private equity could exacerbate cardiology's overuse problem, experts fear

Neuroscience renaissance leads to new crop of psychiatric drugs

entertainment

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Moonlake's readout produced a cash windfall. Risks remain

PEPFAR is under serious threat — and so is global health

Moonlake's readout produced a cash windfall. Risks remain

Popular nasal decongestant doesn't actually relieve congestion

Activists slam private health insurers over coverage restrictions

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Walensky prepares to leave CDC — and Congress — behind

WATCH: Why do bright lights make us see spots?

Bright Health sells Medicare Advantage business to Molina

Are embryos people? Reproductive medicine's future depends on the answer

explore

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Long Covid needs a new name — and a new frame

FDA approves updated Covid vaccines

Study fuels hope CAR

'Vaccine

Virtual repurposing can help discover new uses for existing drugs

explore

leisure time

focus

hotspot